Sevelamer Production Cost Reports

The report provides a detailed analysis essential for establishing a sevelamer production plant. It encompasses all critical aspects necessary for sevelamer production, including the cost of sevelamer production, sevelamer plant cost, sevelamer production costs, and the overall sevelamer production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a sevelamer production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Sevelamer is a non-calcium phosphate binder that is used to control hyperphosphataemia in patients with chronic kidney disease (CKD). It is used in haemodialysis or peritoneal dialysis, by binding dietary phosphate in the gut to prevent its absorption and lower serum phosphorus levels. It is effective without the risks of hypercalcemia or vascular calcification associated with calcium-based binders. It also provides benefits such as reducing LDL and total cholesterol by up to 30%, thereby decreasing inflammation and cardiovascular events. It is available as sevelamer hydrochloride (Renagel) or carbonate (Renvela) in tablet, powder, or suspension forms and taken orally with meals multiple times daily, showing comparable efficacy to other binders but improved long-term tolerability.

The market for sevelamer is fuelled by growing cases of chronic kidney disease (CKD) and end-stage renal disease (ESRD). The rising diabetes, hypertension, and an ageing population contribute to its market growth. The increased awareness of hyperphosphataemia risks, like cardiovascular complications and bone disorders, boosts its demand.

The advancements in patient-friendly formulations (e.g., oral suspensions, generics), expanded dialysis access, and supportive healthcare policies expand its applications. High treatment costs, generic competition lowering prices, and side effect profiles versus alternatives such as calcium binders affect industrial sevelamer procurement.  Other factors such as supply chain reliability for consistent production, regional healthcare infrastructure disparities, reimbursement policies, and R&D also affect its market dynamics.

Raw Material for Sevelamer Production

According to the sevelamer production plant project report, the key raw materials used in the production of sevelamer include poly(allylamine hydrochloride) and 1-chloro-3-methylsulfonyl-2-propanol.

Production Process of Sevelamer

The extensive sevelamer production cost report consists of the following major industrial production process:

1. From poly(allylamine hydrochloride): The production process of sevelamer involves several steps. First, poly(allylamine hydrochloride) is dissolved in deionised water, adjusting the pH to 10-11 with sodium hydroxide to create a basic environment. The resulting solution is added to a toluene solution of the cross-linking agent 1-chloro-3-methylsulfonyl-2-propanol. It is heated under continuous stirring to facilitate the cross-linking reaction that forms the polymer network. After cooling, the mixture is acidified with hydrochloric acid to precipitate the crude product. The crude material is then purified and converted into Sevelamer carbonate.

Sevelamer is a non-absorbed, polymeric amine resin that is available in two salts, sevelamer hydrochloride and sevelamer carbonate. It is a cross-linked poly(allylamine) polymer formed by reacting polyallylamine with epichlorohydrin. It has a polymeric nature instead of a single small molecule. It's both salt sevelamer hydrochloride and carbonate, which are white to off-white. The hydrophilic powders are insoluble in water and are not systemically absorbed. The carbonate salt is also hygroscopic (readily absorbing moisture from the air). All these physical and chemical properties make it useful as a non-calcium phosphate binder used to control hyperphosphataemia.